Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mogamulizumab-induced bone granuloma.
Alaterre C, Philippoteaux C, Toulemonde E, El Maamar Y, Dubois R, Arib I, Carpentier O, Faiz S, Mortier L. Alaterre C, et al. Among authors: toulemonde e. Joint Bone Spine. 2025 Jan;92(1):105782. doi: 10.1016/j.jbspin.2024.105782. Epub 2024 Sep 25. Joint Bone Spine. 2025. PMID: 39332664 No abstract available.
Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas.
Toulemonde E, Chevret S, Battistella M, Neidhardt EM, Nardin C, Le Du F, Meyer N, Véron M, Gambotti L, Lamrani-Ghaouti A, Jamme P, Chaffaut C, De Pontville M, Saada-Bouzid E, Beylot-Barry M, Simon C, Jouary T, Marabelle A, Mortier L. Toulemonde E, et al. Cancer Immunol Immunother. 2023 Aug;72(8):2649-2657. doi: 10.1007/s00262-023-03449-9. Epub 2023 Apr 17. Cancer Immunol Immunother. 2023. PMID: 37067554 Free PMC article.
Efficacy of textile photodynamic therapy for mycosis fungoides.
Toulemonde E, Douxami M, Faiz S, Dubois R, Verhasselt-Crinquette M, Carpentier O, Abi Rached H, Mortier L. Toulemonde E, et al. JAAD Case Rep. 2022 Nov 12;32:11-14. doi: 10.1016/j.jdcr.2022.11.009. eCollection 2023 Feb. JAAD Case Rep. 2022. PMID: 36620497 Free PMC article. No abstract available.
Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial.
Véron M, Chevret S, Grob JJ, Beylot-Barry M, Saiag P, Fléchon A, You B, Maubec E, Jouary T, Toulemonde E, Jamme P, Gambotti L, Lamrani-Ghaouti A, Dupuy A, Lebbe C, Seguin NB, Houede N, Leccia MT, Le Du F, de Pontville M, Gaudy-Marquestre C, Guillot B, Simon C, Marabelle A, Mortier L. Véron M, et al. Among authors: toulemonde e. Eur J Cancer. 2022 Dec;177:103-111. doi: 10.1016/j.ejca.2022.09.013. Epub 2022 Oct 11. Eur J Cancer. 2022. PMID: 36335780 Clinical Trial.